Because of their potential for adoptive transfer without inducing GvHD, several clinical trials are in progress to induce ADCC against B cell lymphoma, pancreatic and other advanced solid tumors, and multiple myeloma via monoclonal antibody/CD16-NK cell combined treatment (105). Here, FCGR3A is linked to plasma cell myeloma.